2024-10-22 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co. is a pharmaceutical company that develops and manufactures a wide range of medicines, including treatments for diabetes, cancer, and autoimmune diseases. 

**1. Performance Compared to S&P 500 (VOO)**

* **Cumulative Return:** LLY (884.77%) significantly outperformed VOO (137.88%).
* **Relative Strength:** LLY is currently trading at a 92.67% percentile relative to its historical performance compared to VOO. 
* **Current Outperformance:** LLY is currently outperforming VOO by 746.89%.

**2. Recent Price Movement**

* **Closing Price:** $917.97
* **5-Day Moving Average:** $918.87
* **20-Day Moving Average:** $907.78
* **60-Day Moving Average:** $900.17

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 65.14, suggesting the stock is currently in overbought territory.
* **PPO (Percentage Price Oscillator):** 0.21, indicating a positive momentum in the price.
* **Delta_Previous_Relative_Divergence:** -1.59, indicating a short-term downward trend in relative strength compared to the broader market.
* **Expected Return:** 47.88%, indicating a potential long-term outperformance compared to the S&P 500 if invested for at least 2 years.

**4. Recent Earnings and Outlook**

| Date       | EPS      | Revenue      |
|------------|----------|--------------|
| 2024-08-08 | 3.29     | 11.30 B$     |
| 2024-04-30 | 2.49     | 8.77 B$     |
| 2023-11-02 | -0.06     | 9.50 B$     |
| 2023-08-08 | 1.96     | 8.31 B$     |

* The latest earnings report for Q2 2024 showed a strong beat on both EPS and revenue estimates, demonstrating continued growth and exceeding market expectations.
* This positive performance reflects the company's strong pipeline of innovative products and its ability to navigate the challenging economic landscape.

**5. News and Recent Issues**

* **Recent Market Outlook:**  Analysts remain bullish on Eli Lilly's future due to its strong growth prospects, innovative drug pipeline, and strong financial performance.
* **Analyst Opinions:**  Several analysts have recently raised their price targets for LLY, reflecting their confidence in the company's future growth potential.
* **Performance Highlights:** Eli Lilly's key products continue to perform well in the market, with some experiencing significant growth. This includes their diabetes treatments, cancer medications, and Alzheimer's drug, Donanemab. 

**6. Overall Analysis**

Eli Lilly and Co. (LLY) presents a compelling investment opportunity. Its strong financial performance, impressive growth potential, and innovative product pipeline position it for continued success in the pharmaceutical sector.  However, it's important to note the recent overbought RSI and the short-term downward trend in relative strength. This suggests that the stock may experience some near-term volatility. However, the long-term outlook remains positive, with strong expected returns for investors willing to hold for the long haul.

**7. Recommendations**

Given its strong fundamentals and growth potential, LLY could be a good addition to a diversified investment portfolio. While the stock is currently overbought and may experience some near-term volatility, its long-term potential remains promising. 

However, potential investors should be aware of these points:

* **Valuation:** The stock is currently trading at a premium valuation compared to its peers.
* **Competition:** The pharmaceutical industry is highly competitive, and Eli Lilly faces numerous challenges from established and emerging competitors.
* **Regulatory Uncertainty:** The regulatory environment for pharmaceuticals is constantly evolving, and any changes could impact the company's business.


Please note that this is not financial advice and investors should conduct thorough research and consult with a financial professional before making any investment decisions. 
